<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934229</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03140-55</org_study_id>
    <nct_id>NCT03934229</nct_id>
  </id_info>
  <brief_title>The Effect of the Probiotic Bifidobacterium Animalis Ssp. Lactis 420 (B420) on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention</brief_title>
  <acronym>QL SlimCap HL</acronym>
  <official_title>The Effect of the Probiotic Bifidobacterium Animalis Ssp. Lactis 420 (B420) on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention: A Randomized, Double-blind, Placebo-controlled, Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danisco France SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danisco France SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, multi-center, parallel group study on
      overweight and obese individuals following healthy lifestyle consisting of calorie-reduced
      diet (20% calorie restriction) and increase in daily activity (1000 steps more per day)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total body fat mass relative change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Difference in total body fat mass relative change from baseline (Visit 2) to 6 months of product intake (Visit 5) between the active vs. placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trunk fat mass change</measure>
    <time_frame>Change from baseline at 2 months, 4 months and 6 months</time_frame>
    <description>Change in trunk fat mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in waist circumference from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Android fat mass change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in android fat mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in lean body mass from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in energy intake from baseline (Visit 2) to 6 months (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass change in individual body regions</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in fat mass in other individual body regions from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass absolute change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in total body fat mass absolute change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in body weight from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in BMI from baseline (Visit 2) to 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in hip circumference from baseline (Visit 2) to, 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5) (absolute and relative)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass relative change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), and 4 months (Visit 4)</time_frame>
    <description>Change in total body fat mass relative change from baseline (Visit 2) to 2 months (Visit 3), and 4 months (Visit 4)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Food intake change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in food intake from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in physical activity (IPAQ) from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Daily activity change</measure>
    <time_frame>Change from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</time_frame>
    <description>Change in daily activity (steps, pedometer/accelerometer) from baseline (Visit 2) to 2 months (Visit 3), 4 months (Visit 4) and 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting glucose levels change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fasting glucose levels from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting insulin levels change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fasting insulin levels from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin resistance change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in insulin resistance from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in glycated hemoglobin HbA1c from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood lipids change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in blood lipids from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation markers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in inflammation markers, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating zonulin change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in circulating zonulin from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Barrier function and endotoxemia markers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in markers of gut barrier function and endotoxemia, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal microbiota change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fecal microbiota from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Fecal metabolites change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in fecal metabolites from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adipose tissue biomarkers change</measure>
    <time_frame>Change from baseline at 6 months</time_frame>
    <description>Change in adipose tissue biomarkers, as specified in Section 4.2.8, from baseline (Visit 2) to 6 months (Visit 5)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bifidobacterium animalis ssp. lactis 420 at 1*10^10 colony forming units (CFU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Daily intake of study product</intervention_name>
    <description>Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period</description>
    <arm_group_label>Group Active</arm_group_label>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary, written, signed, informed consent to participate in the study

          2. Male or female, age between 20 to 65 (inclusive)

          3. BMI between 28.0 and 34.9 (inclusive), of which 1:1 overweight (28.0-29.9):obese
             (30-34.9)

          4. Waist circumference for men of &gt; 102 cm or for women of &gt; 88 cm

          5. Agreement to comply with the protocol and study restrictions

          6. Access to Internet in addition to willingness and ability to use web-based
             questionnaires

          7. Available for all study visits

          8. Females of child-bearing potential required to provide a negative urine pregnancy test
             and agree to use a medically-approved method of birth control, eg. all of the
             following are approved: birth control pill, patch, shot, vaginal ring, mini pill,
             long-acting reversible contraception (LARC) meaning hormonal intrauterine device,
             nonhormonal intrauterine device with copper, subdermal contraceptive implant, condoms,
             cervical cap, diaphragm.

          9. Covered by Health Insurance System and / or in compliance with the recommendations of
             National Law in force relating to biomedical research.

        Exclusion Criteria:

          1. Diagnosed and pharmacologically-treated type 1 and type 2 diabetes (fasting blood
             glucose ≥ 7 mmol/l)

          2. Use of medication/supplements for blood glucose control

          3. Pharmacologically-treated (medication/supplements) hypertension or dyslipidemia

          4. Cardiovascular disease, hypertensive retinopathy, left ventricular dysfunction,
             secondary hypertension, liver dysfunction/disease, kidney dysfunction/disease,
             dementia, thyroid disease, pancreatic disease, history of cancer within past 5 years
             (excluding basal cell carcinoma), anemia, or any other disease or condition which, in
             the Investigator's opinion, could interfere with the results of the study or the
             safety of the subject

          5. Use of drugs or supplements to manage body weight or body fat in the last 3 months

          6. Use of laxatives or fiber supplements in the past 6 weeks.

          7. History of chronic active inflammatory disorders

          8. History of bariatric surgery

          9. History of any chronic gastrointestinal disease (e.g. IBD) or disorders (e.g. IBS,
             constipation, diarrhea), or gastrointestinal reflux disease

         10. Regular use of non-steroidal anti-inflammatory drugs, systemic or inhaled
             corticosteroids, or systemic immunomodulatory drugs

         11. Regular (more than once per week) use of proton pump inhibitors

         12. Recent (last 3 months) or ongoing antibiotic use

         13. Immunosuppression or ongoing therapy causing immunosuppression

         14. Use of probiotic supplements during the previous 6 weeks

         15. Significant change in tobacco, snuff, nicotine and e-cigarette use habits in the past
             3 months or planned cessation of the use of these products during the trial

         16. Use of vitamin D supplementation of ≥100 µg/day

         17. Active or recent (last 3 months) participation in a weight loss program (diet and/or
             exercise)

         18. Weight change (increase or loss) of 3 kg during the past 3 months

         19. Pregnant or planning pregnancy during the study or breastfeeding

         20. Participation in a clinical trial with an investigational product or drug within 60
             days prior to screening

         21. Likeliness to be noncompliant with the protocol

         22. No possibility of contact in case of emergency

         23. Illicit drug users

         24. Alcohol abusers

         25. Administrative or legal supervision

         26. Subject who would receive more than 4500 euros as indemnities for his participation in
             biomedical research within the 12 last months, including the indemnities for the
             present study

         27. Other reasons that, in the opinion of the Investigator, make the participant
             unsuitable for enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CEN nutriment</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Centelles</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Hostalets</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Perelada</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAP Murallas</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 30, 2019</last_update_submitted>
  <last_update_submitted_qc>April 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

